Cdk12 breast cancer

Author: rzmq

August undefined, 2024

WebNational Center for Biotechnology Information WebGene Location [ 1] 17q12. Pathway. Cell cycle control. Gene. CDK12. CDK12 Mutation is present in 1.81% of AACR GENIE cases, with lung adenocarcinoma, prostate …

Targeting CDK12 for Cancer Therapy: Function, …

WebAug 30, 2024 · CDK12 kinase inhibition alters oncogenic transcriptional programs and has antitumor activity in both trastuzumab-sensitive and trastuzumab-resistant HER2 + breast cancer. To elucidate how CDK12 regulates tumorigenesis and trastuzumab response in HER2 + breast cancer, genome-wide CDK12-target genes were investigated by RNA … WebHere we report the development of SR-4835, a highly selective dual inhibitor of CDK12 and CDK13, which disables triple-negative breast cancer (TNBC) cells. Mechanistically, inhibition or loss of CDK12/CDK13 … paleoclimate indicators continental drift

CDK12/13 Inhibitor SR-4835 Is Active in Triple …

WebMar 3, 2024 · Another oncogenic property of overexpressed CDK12 leads to the downregulation of the DNAJB6-L protein (via ALE splicing of its mRNA), which promotes the cell migration and invasiveness of HER2-positive breast cancer cells . The CDK12-specific focal tandem duplications with a high number of duplications and fusions can lead to the … WebJul 20, 2024 · Although CDK12 has only recently emerged as a potential vulnerability for different cancer types including Ewing sarcoma, triple-negative breast cancer, and hepatocellular carcinoma (Iniguez et al., 2024; Quereda et al., 2024; Wang et al., 2024), we describe here a profound CDK12 dependency in a subgroup of patients with CRC. … WebCDK12 cyclin-dependent kinase 12 is a protein kinase that in humans is encoded by the CDK12 gene. This enzyme is a member of cyclin-dependent kinase protein family. … paleoclimate modelling

National Center for Biotechnology Information

Gene expression regulation by CDK12: a versatile kinase in cancer …

WebJun 14, 2024 · CDK12 is a member of the cyclin-dependent kinase family that acts as regulator of DNA damage response gene expression. A c.1047-2A>G splice site variant of the CDK12 gene was recently reported to strongly associate with hereditary breast and ovarian cancer in patients of Tatar ethnic origin. To gain more insight into the potential … WebMay 25, 2024 · In breast cancer cells, ALE splicing by CDK12 regulates the expression of DDR activator ATM and DNAJB6 isoforms, which can influence tumorigenesis when CDK12 is mutated or silenced. In addition to ... うまいものWebApr 8, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data from our CDK12 inhibitor program, demonstrating robust anti-tumor activity of our oral, selective CDK12 inhibitors in models … うまいものいち

"Weba constructed shRNA insert targeting CDK12. Lentiviral particles were produced, carrying these modified pLKO.1- TRC plasmids, and transfected into the MDA-MB-231 breast cancer cell line in an effort to deplete the cells’ expression of CDK12. The results from this study underline the potential of CDK12 disruption as a novel therapeutic ... " - Cdk12 breast cancer

Cdk12 breast cancer

Targeting CDK12 for Cancer Therapy: Function, …

WebCyclin-dependent kinase 12 (CDK12) is a gene that encodes a protein that functions in the phosphorylation of the C-terminal of the large subunit of RNA polymerase II, the … WebJul 27, 2024 · Androgen receptor (AR) signaling inhibitors provide limited survival benefits to patients with prostate cancer (PCa), and worse, few feasible genomic lesions restrict targeted treatment to PCa.

Did you know?

WebOn chromosome 17, the CDK12 gene is located approximately 200kb proximal to the HER2 (ERBB2) oncogene and is frequently co-amplified in breast tumors[36 37]. In cohorts of … WebJun 20, 2024 · Furthermore, CDK12 inhibitors reversed de novo and acquired PARPi resistance in BRCA1-mutant breast cancer cells . 4) PARPi-immunotherapy; Jiao et al and her colleagues revealed that PARPi upregulated PD-L1 expression in breast cancer cell lines via inactivating GSK3β, which in return leading to attenuate anticancer immunity.

WebOn chromosome 17, the CDK12 gene is located approximately 200 kb proximal to the HER2 (ERBB2) oncogene and is frequently coamplified in breast tumours.36 37 In cohorts of primary breast cancer, high CDK12 expression correlated with HER2 status, suggesting oncogenic roles for CDK12 in this context.38 Tumorigenic roles for CDK12 were recently ... WebNov 11, 2024 · In this issue of Cancer Cell, Quereda and colleagues report that a newly developed specific inhibitor of CDK12/13, SR-4835, sensitizes triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in the DNA damage response pathway.

WebOct 5, 2024 · In 2024, it was found that CDK12 inhibition could enhance the sensitivity of HER2+ breast cancer to HER2-tyrosine kinase inhibitors by inhibiting PI3K/AKT [111, 113]. Inhibition of CDK12 can enhance the efficacy of anti-HER2 tyrosine kinase inhibitor Lapatinib, and dual inhibition of HER2/CDK12 may benefit the prognosis of patients with … WebApr 4, 2024 · Abstract. Cyclin-dependent kinase 12 (CDK12) belongs to the cyclin-dependent kinase (CDK) family of serine/threonine protein kinases. The CDK12/cyclin K complex regulates the elongation step of RNA transcription by phosphorylating Ser2 on the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II, and …

WebJun 18, 2024 · CDK12 in Breast Cancer. Increasing evidence shows that CDK12 is closely linked with breast cancer. Interestingly, CDK12 plays distinguishing roles among various subtypes of breast cancer, ...

WebDec 2, 2024 · The novel CDK12/13 inhibitor SR-4835 was effective in mouse models of triple-negative breast cancer. Major Finding: ... Genetic inactivation of CDK12 or CDK13 resulted in a similar phenotype. RNA … paleoclimate modelingWebMar 22, 2024 · For example, ovarian and triple-negative breast cancer cells with the lower expression of CDK12 are more sensitive to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, and a combination ... paleoclimate programsWebJul 10, 2024 · Results. CDK12 genomic alterations were detected in 1.1% of all cases, most frequently in prostate cancer (5.6%), but were also observed at >1% frequency in 11 … paleoclimate researchWebOct 22, 2024 · Choi reported that CDK12 is a novel regulatory factor of tumor stem cells, which can promote tumor initiation and induce anti-HER2 resistance in breast cancer. We analyzed CDK12 expression in 12 ... うまいものいち tvWebDec 9, 2024 · CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, including difficult-to-treat breast, ovarian, colorectal, brain and pancreatic cancers, and is synthetic lethal with PARP, MYC or EWS/FLI inhibition. … paleoclimate scienceWebJan 4, 2024 · CDK12 promotes tumor initiation, invasion, and metastasis, as well as maintains cancer stem cell self-renewal via activating ErbB–PI3K–AKT or WNT/β-catenin signaling in breast cancer. CDK12 … うまいものいちいかWebJul 13, 2024 · For example, ovarian and triple-negative breast cancer cells with the lower expression of CDK12 are more sensitive to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, and a combination treatment of olaparib and dinaciclib, a nonselective CDK12 inhibitor, synergistically suppressed tumor growth in PDX models. うまいものあり孝太郎東口